The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Anita R Ollie - One of the best experts on this subject based on the ideXlab platform.
-
effects of ocular carteolol and timolol on plasma High Density Lipoprotein cholesterol level
American Journal of Ophthalmology, 1993Co-Authors: Sharon F Freedman, Neil J Freedman, Bruce M Shields, Bruce Lobaugh, Gregory P Samsa, Edwin U Keates, Anita R OllieAbstract:Fifty-eight healthy, normolipidemic adult men participated in a prospective, masked, randomized crossover study designed to compare the effects of two topical nonselective β-adrenergic antagonists, Carteolol and timolol, on plasma High-Density Lipoprotein cholesterol levels. Two eight-week treatment periods were separated by an eight-week drug-free period. Carteolol 1.0% or timolol 0.5% was used, one drop twice daily, in both eyes without nasolacrimal occlusion. Fresh plasma was assayed for levels of total cholesterol, High-Density Lipoprotein cholesterol, low-Density Lipoprotein cholesterol, triglycerides, and apoLipoproteins A-I and B-100. With indistinguishable effects on intraocular pressure, Carteolol and timolol induced different (P = .013) decrements in High-Density Lipoprotein cholesterol levels. Carteolol treatment decreased High-Density Lipoprotein cholesterol levels by 3.3% (-0.04 mmol/l) and raised the ratio of total to High-Density Lipoprotein cholesterol levels by 4.0% (0.15 unit); timolol treatment decreased High-Density Lipoprotein cholesterol levels by 8.0% (-0.10 mmol/l) and raised the ratio of total to High-Density Lipoprotein cholesterol levels by 10.0% (0.37 unit). There was no differential drug effect on the other lipid variables measured. Ocular nonselective β-adrenergic antagonist therapy can produce clinically relevant decrements in High-Density Lipoprotein cholesterol levels in healthy men.
Ping Wang - One of the best experts on this subject based on the ideXlab platform.
-
Correlation study of pulmonary embolism and High-Density Lipoprotein cholesterol.
Clinical cardiology, 2010Co-Authors: Yupeng Wang, Ping WangAbstract:Background It is currently thought that pulmonary embolism and deep vein thrombosis are different manifestations of the same pathological process of venous thromboembolism. Venous thromboembolism has a negative correlation with High-Density Lipoprotein cholesterol. Hypothesis Pulmonary embolism has a negative correlation with the level of High-Density Lipoprotein cholesterol. Methods A total of 90 patients with pulmonary embolism, diagnosed and treated at a single center, were retrospectively analyzed for the present study. Among them were 57 cases of pulmonary arterial trunk embolism in group A and 33 cases of pulmonary arterial non-trunk embolism in group B. Results The results showed that the level of High-Density Lipoprotein cholesterol decreased markedly in patients with pulmonary arterial trunk embolism as compared to those with pulmonary arterial non-trunk embolism. A stepwise logistic regression analysis was performed upon the relationship between pulmonary arterial trunk embolism and multiple factors. The results showed that a pulmonary arterial trunk embolism had a negative correlation with the level of High-Density Lipoprotein cholesterol and a positive correlation with triglyceride and High sensitivity C-reactive protein. Conclusions Pulmonary arterial trunk embolism is negatively correlated with the level of High-Density Lipoprotein cholesterol. Copyright © 2010 Wiley Periodicals, Inc.
Mark S Cohen - One of the best experts on this subject based on the ideXlab platform.
-
synthetic High Density Lipoprotein nanoconjugate targets neuroblastoma stem cells blocking migration and self renewal
Surgery, 2018Co-Authors: Chitra Subramanian, Peter T White, Rui Kuai, Avinaash Kalidindi, Valerie P Castle, James J Moon, Barbara N Timmermann, Anna Schwendeman, Mark S CohenAbstract:Background Pathways critical for neuroblastoma cancer stem cell function are targeted by 4,19,27-triacetyl withalongolide A (WGA-TA). Because neuroblastoma cells and their cancer stem cells Highly overexpress the scavenger receptor class B type 1 receptor that binds to synthetic High-Density Lipoprotein, we hypothesized that a novel mimetic synthetic High-Density Lipoprotein nanoparticle would be an ideal carrier for the delivery of 4,19,27-triacetyl withalongolide to neuroblastoma and neuroblastoma cancer stem cells. Methods Expression of scavenger receptor class B type 1 in validated human neuroblastoma cells was evaluated by quantitative polymerase chain reaction (qPCR) and Western blot. In vitro cellular uptake of synthetic High-Density Lipoprotein nanoparticles was observed with a fluorescence microscope. In vivo biodistribution of synthetic High-Density Lipoprotein nanoparticles was investigated with IVIS imaging. Self-renewal and migration/invasion were assessed by sphere formation and Boyden chamber assays, respectively. Viability was analyzed by CellTiter-Glo assay. Cancer stem cell markers were evaluated by flow cytometry. Results qPCR and Western blot analysis revealed a Higher level of scavenger receptor class B type 1 expression and drug uptake in N-myc amplified neuroblastoma cells. In vitro uptake of synthetic High-Density Lipoprotein was almost completely blocked by excess synthetic High-Density Lipoprotein. The synthetic High-Density Lipoprotein nanoparticles mainly accumulated in the tumor and liver, but not in other organs. Synthetic HDL-4,19,27-triacetyl withalongolide showed a 1,000-fold Higher potency than the carrier (synthetic High-Density Lipoprotein) alone (P Conclusion Synthetic High-Density Lipoprotein is a promising platform to improve the delivery of anticancer drug 4,19,27-triacetyl withalongolide A to neuroblastomas and neuroblastoma cancer stem cells through SR-B1 targeting in vitro and in vivo.
Prediman K Shah - One of the best experts on this subject based on the ideXlab platform.
-
High-Density Lipoprotein mimetics: focus on synthetic High-Density Lipoprotein.
The American journal of cardiology, 2007Co-Authors: Prediman K ShahAbstract:Epidemiologic studies show an inverse relation between High-Density Lipoprotein (HDL) cholesterol levels and coronary artery disease, and proof-of-concept experimental studies suggest that HDL and its apoLipoproteins, specifically apoLipoprotein (apo) A-I , have atheroprotective effects. Atheroprotective effects of HDL are attributed to its ability to remove macrophage cholesterol by stimulating reverse cholesterol transport as well as anti-inflammatory and antioxidant effects. Several different strategies are currently being pursued to exploit the vascular-protective effects of HDL. One such approach involves direct administration of synthetic reconstituted HDL made from linking phospholipid carriers with recombinant mutant apoA-I or plasma-derived wild-type apoA-I.
-
Emerging strategies for increasing High-Density Lipoprotein.
The American journal of cardiology, 2006Co-Authors: James S. Forrester, Prediman K ShahAbstract:High-Density Lipoprotein cholesterol is a potent and independent epidemiologic risk factor and is a proved antiatherosclerotic agent in animal models of atherosclerosis, acting through the principal mechanisms of accelerating cholesterol efflux and inhibiting oxidation and inflammation. Lifestyle modification increases serum levels by 5% to 15%, whereas niacin, the drug most widely used to increase High-Density Lipoprotein cholesterol, increases it by 25% to 35% at the Highest doses. This review examines the potent methods of increasing High-Density Lipoprotein and/or enhancing reverse cholesterol transport, including cholesterol ester transfer protein inhibitors, apoLipoprotein A-I Milano, D4F, the dual peroxisome proliferator–activated receptor agonists, and rimonabant, that are now in clinical trials. In conclusion, these new agents, used alone or in combination with existing therapies, carry the potential to markedly reduce the incidence of new coronary disease and cardiac events in this decade.
Sharon F Freedman - One of the best experts on this subject based on the ideXlab platform.
-
effects of ocular carteolol and timolol on plasma High Density Lipoprotein cholesterol level
American Journal of Ophthalmology, 1993Co-Authors: Sharon F Freedman, Neil J Freedman, Bruce M Shields, Bruce Lobaugh, Gregory P Samsa, Edwin U Keates, Anita R OllieAbstract:Fifty-eight healthy, normolipidemic adult men participated in a prospective, masked, randomized crossover study designed to compare the effects of two topical nonselective β-adrenergic antagonists, Carteolol and timolol, on plasma High-Density Lipoprotein cholesterol levels. Two eight-week treatment periods were separated by an eight-week drug-free period. Carteolol 1.0% or timolol 0.5% was used, one drop twice daily, in both eyes without nasolacrimal occlusion. Fresh plasma was assayed for levels of total cholesterol, High-Density Lipoprotein cholesterol, low-Density Lipoprotein cholesterol, triglycerides, and apoLipoproteins A-I and B-100. With indistinguishable effects on intraocular pressure, Carteolol and timolol induced different (P = .013) decrements in High-Density Lipoprotein cholesterol levels. Carteolol treatment decreased High-Density Lipoprotein cholesterol levels by 3.3% (-0.04 mmol/l) and raised the ratio of total to High-Density Lipoprotein cholesterol levels by 4.0% (0.15 unit); timolol treatment decreased High-Density Lipoprotein cholesterol levels by 8.0% (-0.10 mmol/l) and raised the ratio of total to High-Density Lipoprotein cholesterol levels by 10.0% (0.37 unit). There was no differential drug effect on the other lipid variables measured. Ocular nonselective β-adrenergic antagonist therapy can produce clinically relevant decrements in High-Density Lipoprotein cholesterol levels in healthy men.